There are currently 46 active clinical trials seeking participants for Amyotrophic Lateral Sclerosis research studies. The states with the highest number of trials for Amyotrophic Lateral Sclerosis participants are California, Florida, Pennsylvania and New York.
NYSCF Scientific Discovery Biobank
NCT06203106
Recruiting
The New York Stem Cell Foundation (NYSCF) Research Institute is performing this research to accelerate diverse disease research using cells from the body (such as skin or blood cells) to make stem cells and other types of cells, conduct research on the samples, perform genetic testing, and store the samples for future use. Through this research, researchers hope to identify future treatments or even cures for the major diseases of our time.
Gender:
ALL
Ages:
30 days and above
Trial Updated:
02/27/2025
Locations: New York Stem Cell Foundation Research Institute, New York, New York
Conditions: ALS, Amyotrophic Lateral Sclerosis, Alzheimer Disease, Alzheimer Disease, Early Onset, Alzheimer Disease, Late Onset, Batten Disease, Corticobasal Degeneration, Dementia, Frontotemporal Dementia, Huntington Disease, Lewy Body Disease, Multiple Sclerosis, Multiple System Atrophy, Parkinson Disease, Parkinson's Disease and Parkinsonism, Progressive Supranuclear Palsy, INAD, Diabetes, Diabetes Mellitus, Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1, Macular Degeneration, Ovarian Cancer, Cervical Cancer, Uterine Cancer, Vaginal Cancer, Vulvar Cancer, PTSD, Post Traumatic Stress Disorder
Register for Updates
The Pre-symptomatic Familial Amyotrophic Lateral Sclerosis (Pre-fALS) Study
NCT00317616
Recruiting
Pre-fALS is a prospective natural history and biomarker study of people not yet affected with ALS, but who are at genetic risk for developing ALS. The investigators aim to recruit unaffected (healthy) people from familial ALS (fALS) pedigrees in which a known genetic mutation associated with ALS has been identified; for this study, a fALS pedigree is one with two biologically related individuals who have or have had ALS and/or FTD. Individuals who may be at genetic risk for ALS and who belong to... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/25/2025
Locations: University of Miami, Miami, Florida
Conditions: Amyotrophic Lateral Sclerosis
Register for Updates
Clinical Research in ALS Study
NCT00136500
Recruiting
CRiALS is an umbrella protocol through which people are recruited to participate in a range of research studies being conducted by the ALS Research Collaboration (ARC).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/25/2025
Locations: University of Miami, Miami, Florida
Conditions: Amyotrophic Lateral Sclerosis
Register for Updates
BrainGate2: Feasibility Study of an Intracortical Neural Interface System for Persons with Tetraplegia
NCT00912041
Recruiting
The purpose of this study is to obtain preliminary device safety information and demonstrate proof of principle (feasibility) of the ability of people with tetraplegia to control a computer cursor and other assistive devices with their thoughts.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
02/19/2025
Locations: University of California, Davis, Sacramento, California +4 locations
Conditions: Tetraplegia, Spinal Cord Injuries, Amyotrophic Lateral Sclerosis, Brain Stem Infarctions, Locked in Syndrome, Muscular Dystrophy
Register for Updates
Oral Intake of Enteral Nutrition Formula Preceding Placement and Feeding Via GTube and Its Impact on Formula Intolerance in PALS
NCT06609213
Recruiting
The main objective of the proposed study is to evaluate if oral intake of EN formula preceding Gtube placement will impact tolerance upon placement and feeding via Gtube in pALS. This single arm intervention study all participants will receive the intervention and researchers will utilize validated indicators combined with clinical expertise to assess gastrointestinal symptoms of feeding intolerance before and after the intervention. The main questions this study aims to answer are: 1. Wil par... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/17/2025
Locations: Nova Southeastern University, Cathy J, Husman ALS Center, Fort Lauderdale, Florida
Conditions: Amyotrophic Lateral Sclerosis, Gastrointestinal Intolerance, Enteral Nutrition Therapy
Register for Updates
Evaluating Verbal Communication in Structured Interactions: Theoretical and Clinical Implications
NCT06266403
Recruiting
The goal of this clinical trial is to learn about the effect of communicative interaction on verbal communication in people with amyotrophic lateral sclerosis (ALS) and age-matched speakers. The question is, What are the effects of communicative interaction on verbal communication in people with ALS? Participants will read words and sentences while they are in a solo setting and interactive setting.
Gender:
ALL
Ages:
Between 18 years and 90 years
Trial Updated:
01/09/2025
Locations: Speech Core, Pennsylvania State University, University Park, Pennsylvania
Conditions: Amyotrophic Lateral Sclerosis
Register for Updates
Target ALS Biomarker Study; Longitudinal Biofluids, Clinical Measures, and At Home Measures
NCT05137665
Recruiting
The goal of the study is to generate a biorepository of longitudinal biofluids-blood (plasma and serum), cerebral spinal fluid (CSF) and urine linked to genetics and longitudinal clinical information that are made available to the research community. To accomplish these goals, we will enroll 800 Amyotrophic Lateral Sclerosis (ALS) patients and 200 healthy controls from sites globally, over a 5 year time frame. Additionally, speech and motor function and spirometry measures will be collected bi-w... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/26/2024
Locations: Barrow Neurological Institute, Phoenix, Arizona +11 locations
Conditions: Amyotrophic Lateral Sclerosis, Movement Disorders, Degenerative Disorder, Motor Neuron Disease
Register for Updates
Biospecimen Biorepository for the Study of ALS, ALS-FTD and Similar Neurodegenerative Disorders
NCT05116943
Recruiting
The purpose of this study is to collect CSF and blood samples that can be used in future research studies to identify potential biomarkers in blood and cerebrospinal fluid (CSF) collected in Amyotrophic Lateral Sclerosis (ALS) patients.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/09/2024
Locations: Mayo Clinic in Florida, Jacksonville, Florida
Conditions: Amyotrophic Lateral Sclerosis
Register for Updates
Feasibility of the BrainGate2 Neural Interface System in Persons With Tetraplegia
NCT05724173
Recruiting
The purpose of this study is to obtain preliminary device safety information and demonstrate proof of principle (feasibility) of the ability of people with tetraplegia to control a computer cursor and other assistive devices with their thoughts.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
11/27/2024
Locations: Stanford University School of Medicine, Stanford, California +1 locations
Conditions: Anarthria, Dysarthria, Tetraplegia, Spinal Cord Injuries, Amyotrophic Lateral Sclerosis, Brain Stem Infarctions, Locked in Syndrome, Muscular Dystrophies
Register for Updates
Feasibility of the BrainGate2 Neural Interface System in Persons With Tetraplegia (BG-Speech-02)
NCT06094205
Recruiting
The goal of this study is to improve our understanding of speech production, and to translate this into medical devices called intracortical brain-computer interfaces (iBCIs) that will enable people who have lost the ability to speak fluently to communicate via a computer just by trying to speak.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
11/27/2024
Locations: University of California, Davis, Sacramento, California
Conditions: Anarthria, Dysarthria, Tetraplegia, Spinal Cord Injuries, Amyotrophic Lateral Sclerosis, Brain Stem Infarctions, Locked-in Syndrome, Muscular Dystrophies
Register for Updates
FLOWER: Following Longitudinal Outcomes With Epidemiology for Rare Diseases
NCT06539169
Recruiting
FLOWER is a completely virtual, nationwide, real-world observational study to collect, annotate, standardize, and report clinical data for rare diseases. Patients participate in the study by electronic consent (eConsent) and sign a medical records release to permit data collection. Medical records are accessed from institutions directly via eFax or paper fax, online from patient electronic medical record (EMR) portals, direct from DNA/RNA sequencing and molecular profiling vendors, and via elect... Read More
Gender:
ALL
Ages:
All
Trial Updated:
11/12/2024
Locations: xCures, Los Altos, California
Conditions: Alpha-Thalassemia, Beta-Thalassemia, Amyloidosis, Amyotrophic Lateral Sclerosis, Creutzfeld-Jakob Disease, Cystic Fibrosis, Duchenne Muscular Dystrophy, Early-Onset Alzheimer Disease, Ehlers-Danlos Syndrome, Huntington Disease, Gaucher Disease, GM1 Gangliosidosis, Myasthenia Gravis, Pompe Disease, Sickle Cell Disease, Transthyretin Amyloid Cardiomyopathy, Rare Diseases
Register for Updates
Safety, Tolerability, and Exploratory Efficacy Study of Intrathecally Administered Gene Therapy AMT-162 in Adult Participants with SOD1 Amyotrophic Lateral Sclerosis (SOD1-ALS)
NCT06100276
Recruiting
This is the study of AMT-162 in Participants with SOD1-ALS and is designed to evaluate the safety, tolerability, and exploratory efficacy of intrathecally administered gene therapy AMT-162. AMT-162-001 is a Phase 1/2, multi-center, single ascending dose study.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/08/2024
Locations: University of California Irvine, Irvine, California +9 locations
Conditions: Amyotrophic Lateral Sclerosis
Register for Updates